Search: onr:"swepub:oai:DiVA.org:umu-164100" >
Health-related qual...
Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.
-
Brandberg, Yvonne (author)
-
- Andersson, Anne, 1966- (author)
- Umeå universitet,Onkologi
-
Bjohle, Judith (author)
-
show more...
-
Bosch, Ana (author)
-
Carlsson, Lena (author)
-
- Dreifaldt, Ann Charlotte, 1964- (author)
- Örebro universitet,Institutionen för medicinska vetenskaper
-
Einbeigi, Zakaria (author)
-
Fredholm, Hanna (author)
-
Isaksson-Friman, Erika (author)
-
Foukakis, Theodoros (author)
-
Elinder, Ellinor (author)
-
Hellstrom, Mats (author)
-
Johansson, Hemming (author)
-
Lekberg, Tobias (author)
-
Lindman, Henrik (author)
-
Bergh, Jonas C. S. (author)
-
Hatschek, Thomas (author)
-
show less...
-
(creator_code:org_t)
- American Society of Clinical Oncology, 2019
- 2019
- English.
-
In: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 37:15, s. 583-583
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: Neoadjuvant therapy combining docetaxel, trastuzumab and pertuzumab (DTP) was compared to trastuzumab emtansine (T-DM1) in the randomized phase 2 PREDIX HER2 trial. Patients, ≥18 years with HER2 positive breast cancer, ≥20mm or with verified lymph node metastases, were randomized to six courses of DTP (Standard arm) or T-DM1 (Experimental arm). Primary endpoint was pathological objective response to primary medical therapy at post-treatment surgery. Health related quality of life (HRQoL) was a secondary outcome, and is of specific interest as there was no difference between the randomization groups regarding the main endpoint (results presented in a separate abstract sent to ASCO 2019, Bergh et al.). Methods: Of 202 randomized patients, 190 are available for evaluation at this point. HRQoL was measured, using EORTC QLQ-C30 + EORTC QLQ-BR23, at baseline before randomization and after six courses. Results: No differences between the randomization arms were found at baseline. Results after six courses, based on 163 patients (86%) and adjusted to baseline values, revealed statistical significant differences (p≤0.01), favoring the experimental T-DM1 arm on 7 out of 15 of the EORTC QLQ-C30 variables (Physical functioning, Role functioning, Social functioning, Global quality of Life, Fatigue, Dyspnea, and Diarrhea). For the breast cancer specific questionnaire (EORTC-BR23), the experimental arm scored statistically significantly better on 5 out of 7 subscales (Body image, Sexual functioning, Sexual enjoyment, Systemic therapy side effects and Upset by hair loss). All of the statistical significant differences were of moderate or large clinical significance (≥10 scale scores). No differences between the randomization arms were found for the remaining HRQoL variables. Conclusions: The experimental arm reported better HRQoL than the control arm after six courses. Trastuzumab emtansine may be a useful treatment alternative due to better HRQoL and lower toxicity. Clinical trial information: NCT02568839.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- vet (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Brandberg, Yvonn ...
-
Andersson, Anne, ...
-
Bjohle, Judith
-
Bosch, Ana
-
Carlsson, Lena
-
Dreifaldt, Ann C ...
-
show more...
-
Einbeigi, Zakari ...
-
Fredholm, Hanna
-
Isaksson-Friman, ...
-
Foukakis, Theodo ...
-
Elinder, Ellinor
-
Hellstrom, Mats
-
Johansson, Hemmi ...
-
Lekberg, Tobias
-
Lindman, Henrik
-
Bergh, Jonas C. ...
-
Hatschek, Thomas
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Journal of Clini ...
- By the university
-
Umeå University
-
Örebro University
-
Karolinska Institutet